Global Biopharmaceutical Market Report & Forecast (2017-2021)



The global biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today hundreds of biopharmaceuticals have already been approved and many more are in late stages of clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s multibillion dollar revenues and strong growth rates in previous years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years.

biopharmaceutical market

The study covers the market analysis of various segments and sub-segments of the biopharmaceutical industry based on class and key indicative areas. Recombinant proteins currently represent the biggest segment on the basis of class accounting for the majority of the global biopharmaceutical sales. Recombinant proteins are followed by monoclonal antibodies and purified proteins. On the basis of key indicative and therapeutic application areas for biopharmaceuticals, autoimmune diseases represent the largest segment followed by oncology. With most of the current and future monoclonal antibodies targeted against autoimmune diseases such as rheumatoid arthritis and oncology, autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.

The biopharmaceutical market is largely dominated by the US accounting for nearly half of the total global sales. The other top markets include Germany, Japan, France, Italy, Spain, UK and Canada. Moreover, increasing disposable incomes and a larger access to healthcare insurance, the market for biopharmaceuticals is also expected to expand and offer great opportunities and growth prospects across various emerging markets over the next few years. The report has also provided a robust analysis of the key players operating in the global biopharmaceutical market. Some of the key players analysed in this report include: Roche, Amgen, Novo Nordisk, AbbVie and Sanofi.

IMARC’s new report “Global Biopharmaceutical Market Report & Forecast (2017-2021)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2021. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.

biopharmaceutical market report

 

What We Have Achieved in this Report?

Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market

Key Aspects Analyzed:

  • Driving Factors
  • Restraining Factors
  • Market Opportunities
  • Threats

 

Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics

Regions/Countries Covered:

North America: United States and Canada

Latin America: Mexico, Brazil and Argentina

Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey

Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia

Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins

 

Focus of the Analysis for Each Country:

  • Total Market Performance
  • Performance of Various Classes
  • Performance of Top Players
  • Market Forecast

 

Key Questions Answered in this Report:

 

  • What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
  • What are the key opportunities and threats faced by the biopharmaceutical industry?
  • What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
  • Which are the world’s largest biopharmaceutical markets?
  • Which are the world’s fastest growing biopharmaceutical markets?
  • What is the structure and composition of various biopharmaceutical markets across the globe?
  • Which are the world’s largest biopharmaceutical segments?
  • Which are the world’s fastest growing biopharmaceutical segments?
  • Who are the world’s largest biopharmaceutical companies and how have they performed in recent years?

1 Preface
2 Research Methodology and Market Definitions
3 Executive Summary
4 Introduction

5 Global Biopharmaceutical Market
    5.1 Market Performance and Forecast
        5.1.1 Current Performance (2009-2016)
        5.1.2 Market Forecast (2017-2021)
    5.2 Market by Region
        5.2.1 Current Performance (2009-2016)
        5.2.2 Market Forecast (2017-2021)
    5.3 Market by Indication
        5.3.1 Autoimmune Diseases
        5.3.2 Oncology
        5.3.3 Metabolic Disorders
        5.3.4 Others
    5.4 Market by Class
        5.4.1 Recombinant Proteins
            5.4.1.1 Current Performance (2009-2016)
            5.4.1.2 Market Forecast (2017-2021)
        5.4.2 Monoclonal Antibodies
            5.4.2.1 Current Performance (2009-2016)
            5.4.2.2 Market Forecast (2017-2021)
        5.4.3 Purified Proteins
            5.4.3.1 Current Performance (2009-2016)
            5.4.3.2 Market Forecast (2017-2021)
    5.5 Competitive Landscape
        5.5.1 Top Biopharmaceutical Players
            5.5.1.1 Roche
                5.5.1.1.1 Company Overview
                5.5.1.1.2 Key Financials
            5.5.1.2 Amgen
                5.5.1.2.1 Company Overview
                5.5.1.2.2 Key Financials
            5.5.1.3 Novo Nordisk
                5.5.1.3.1 Company Overview
                5.5.1.3.2 Key Financials
            5.5.1.4 AbbVie
                5.5.1.4.1 Company Overview
                5.5.1.4.2 Key Financials
            5.5.1.5 Sanofi S.A
                5.5.1.5.1 Company Overview
                5.5.1.5.2 Key Financials
            5.5.2 Top Biopharmaceutical Drugs
                5.5.2.1 Humira
                5.5.2.2 Enbrel
                5.5.2.3 Rituxan
                5.5.2.4 Avastin
                5.5.2.5 Lantus
    5.6 Value Chain Analysis
    5.7 Porter’s Five Forces Analysis
        5.7.1 Overview
        5.7.2 Bargaining Power of Buyers
        5.7.3 Bargaining Power of Suppliers
        5.7.4 Degree of Rivalry
        5.7.5 Threat of New Entrants
        5.7.6 Threat of Substitutes
6 North America
    6.1 United States
        6.1.1 Market Performance (2009-2016)
        6.1.2 Market by Class
            6.1.2.1 Recombinant Proteins
             6.1.2.2 Monoclonal Antibodies
            6.1.2.3 Purified Proteins
        6.1.3 Performance of Top Players
        6.1.4 Market Forecast (2017-2021)
    6.2 Canada
        6.2.1 Market Performance (2009-2016)
        6.2.2 Market by Class
            6.2.2.1 Recombinant Proteins
            6.2.2.2 Monoclonal Antibodies
            6.2.2.3 Purified Proteins
        6.2.3 Performance of Top Players
        6.2.4 Market Forecast (2017-2021)
7 Latin America
    7.1 Mexico
        7.1.1 Market Performance (2009-2016)
        7.1.2 Market by Class
            7.1.2.1 Recombinant Proteins
            7.1.2.2 Monoclonal Antibodies
            7.1.2.3 Purified Proteins
        7.1.3 Performance of Top Players
        7.1.4 Market Forecast (2017-2021)
    7.2 Brazil
        7.2.1 Market Performance (2009-2016)
        7.2.2 Market by Class
            7.2.2.1 Recombinant Proteins
            7.2.2.2 Monoclonal Antibodies
            7.2.2.3 Purified Proteins
        7.2.3 Performance of Top Players
        7.2.4 Market Forecast (2017-2021)
    7.3 Argentina
        7.3.1 Market Performance (2009-2016)
        7.3.2 Market by Class
            7.3.2.1 Recombinant Proteins
            7.3.2.2 Monoclonal Antibodies
            7.3.2.3 Purified Proteins
        7.3.3 Performance of Top Players
        7.3.4 Market Forecast (2017-2021)
8 Europe
    8.1 Germany
        8.1.1 Market Performance (2009-2016)
        8.1.2 Market by Class
            8.1.2.1 Recombinant Proteins
            8.1.2.2 Monoclonal Antibodies
            8.1.2.3 Purified Proteins
        8.1.3 Performance of Top Players
        8.1.4 Market Forecast (2017-2021)
    8.2 France
        8.2.1 Market Performance (2009-2016)
        8.2.2 Market by Class
            8.2.2.1 Recombinant Proteins
            8.2.2.2 Monoclonal Antibodies
            8.2.2.3 Purified Proteins
        8.2.3 Performance of Top Players
        8.2.4 Market Forecast (2017-2021)
    8.3 Italy
        8.3.1 Market Performance (2009-2016)
        8.3.2 Market by Class
            8.3.2.1 Recombinant Proteins
            8.3.2.2 Monoclonal Antibodies
            8.3.2.3 Purified Proteins
        8.3.3 Performance of Top Players
        8.3.4 Market Forecast (2017-2021)
    8.4 Spain
        8.4.1 Market Performance (2009-2016)
        8.4.2 Market by Class
            8.4.2.1 Recombinant Proteins
            8.4.2.2 Monoclonal Antibodies
            8.4.2.3 Purified Proteins
        8.4.3 Performance of Top Players
        8.4.4 Market Forecast (2017-2021)
    8.5 United Kingdom
        8.5.1 Market Performance (2009-2016)
        8.5.2 Market by Class
            8.5.2.1 Recombinant Proteins
            8.5.2.2 Monoclonal Antibodies
            8.5.2.3 Purified Proteins
        8.5.3 Performance of Top Players
        8.5.4 Market Forecast (2017-2021)
    8.6 Russia
        8.6.1 Market Performance (2009-2016)
        8.6.2 Market by Class
            8.6.2.1 Recombinant Proteins
            8.6.2.2 Monoclonal Antibodies
            8.6.2.3 Purified Proteins
        8.6.3 Performance of Top Players
        8.6.4 Market Forecast (2017-2021)
    8.7 Turkey
        8.7.1 Market Performance (2009-2016)
        8.7.2 Market by Class
            8.7.2.1 Recombinant Proteins
            8.7.2.2 Monoclonal Antibodies
            8.7.2.3 Purified Proteins
        8.7.3 Performance of Top Players
        8.7.4 Market Forecast (2017-2021)
9 Asia Pacific
    9.1 Japan
        9.1.1 Market Performance (2009-2016)
        9.1.2 Market by Class
            9.1.2.1 Recombinant Proteins
            9.1.2.2 Monoclonal Antibodies
            9.1.2.3 Purified Proteins
        9.1.3 Performance of Top Players
        9.1.4 Market Forecast (2017-2021)
    9.2 China
        9.2.1 Market Performance (2009-2016)
        9.2.2 Market by Class
            9.2.2.1 Recombinant Proteins
            9.2.2.2 Monoclonal Antibodies
            9.2.2.3 Purified Proteins
        9.2.3 Performance of Top Players
        9.2.4 Market Forecast (2017-2021)
    9.3 Australia
        9.3.1 Market Performance (2009-2016)
        9.3.2 Market by Class
            9.3.2.1 Recombinant Proteins
            9.3.2.2 Monoclonal Antibodies
            9.3.2.3 Purified Proteins
        9.3.3 Performance of Top Players
        9.3.4 Market Forecast (2017-2021)
    9.4 South Korea
        9.4.1 Market Performance (2009-2016)
        9.4.2 Market by Class
            9.4.2.1 Recombinant Proteins
            9.4.2.2 Monoclonal Antibodies
            9.4.2.3 Purified Proteins
        9.4.3 Performance of Top Players
        9.4.4 Market Forecast (2017-2021)
    9.5 India
        9.5.1 Market Performance (2009-2016)
        9.5.2 Market by Class
            9.5.2.1 Recombinant Proteins
            9.5.2.2 Monoclonal Antibodies
            9.5.2.3 Purified Proteins
        9.5.3 Performance of Top Players
        9.5.4 Market Forecast (2017-2021)
    9.6 Indonesia
        9.6.1 Market Performance (2009-2016)
        9.6.2 Market by Class
            9.6.2.1 Recombinant Proteins
            9.6.2.2 Monoclonal Antibodies
            9.6.2.3 Purified Proteins
        9.6.3 Performance of Top Players
        9.6.4 Market Forecast (2017-2021)
10 SWOT Analysis
    10.1 Strengths
        10.1.1    High Efficacy and Target Oriented Attack
        10.1.2 Strong Potential to Achieve Blockbuster 
        10.1.3    Limited Generic Threat
        10.1.4 High Approval Success Rates
    10.2 Weaknesses
        10.2.1 Inconvenient Drug Delivery
        10.2.2    Short Half Lives
        10.2.3 Second Line of Therapy
        10.2.4 High Cost of Therapy
        10.2.5 Incidence of Unfavorable Side Effects
    10.3 Opportunities
        10.3.1 Diseases with High Unmet Needs
        10.3.2    Approval into Additional Indications
        10.3.3 Emerging Markets
        10.3.4 New Approvals and a Strong Pipeline
    10.4 Threats
        10.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
        10.4.2 Biosimilars
        10.4.3 Limited and Conditional Reimbursement
        10.4.4 Uncertainties in the Economic Environment


List of Figures

Figure 3-1: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 4-1: Complexity of Biopharmaceuticals
Figure 4-2: Sources of Biopharmaceuticals
Figure 5-1: Global: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 5-2: Global: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 5-3: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2016
Figure 5-4: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2021
Figure 5-5: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2016
Figure 5-6: Global: Autoimmune Biopharmaceutical Market (in Million US$), 2016 & 2021
Figure 5-7: Global: Oncology Biopharmaceutical Market (in Million US$), 2016 & 2021
Figure 5-8: Global: Metabolic Disorders Biopharmaceutical Market (in Million US$), 2016 & 2021
Figure 5-9: Global: Others Biopharmaceutical Market (in Million US$), 2016 & 2021
Figure 5-10: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 5-11: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2017-2021
Figure 5-12: Global: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 5-13: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 5-14: Global: Recombinant Proteins Market Forecast (in Million US$), 2017-2021
Figure 5-15: Global: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 5-16: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 5-17: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2017-2021
Figure 5-18: Global: Purified Proteins Market (in Million US$), 2009-2016
Figure 5-19: Global: Purified Proteins Market: Sales Share by Class (in %), 2016
Figure 5-20: Global: Purified Proteins Market Forecast (in Million US$), 2017-2021
Figure 5-21: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 5-22: Roche: Sales Value Trend (in Billion US$), 2011-2015
Figure 5-23: Roche: Revenue Breakup by Region (in %), 2015
Figure 5-24: Amgen: Sales Value Trend (in Billion US$), 2011-2015
Figure 5-25: Amgen: Revenue Breakup by Region (in %), 2015
Figure 5-26: Novo Nordisk: Sales Value Trend (in Billion US$), 2011-2015
Figure 5-27: Novo Nordisk: Revenue Breakup by Region (in %), 2015
Figure 5-28: AbbVie: Sales Value Trend (in Billion US$), 2011-2015
Figure 5-29: AbbVie: Revenue Breakup by Region (in %), 2015
Figure 5-30: Sanofi S.A: Sales Value Trend (in Billion US$), 2011-2015
Figure 5-31: Sanofi S.A: Revenue Breakup by Region (in %), 2015
Figure 5-32: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %), 2016
Figure 5-33: Global: Humira Market: Sales Value (in Billion US$), 2010-2015
Figure 5-34: Global: Enbrel Market: Sales Value (in Billion US$), 2010-2015
Figure 5-35: Global: Rituxan Market: Sales Value (in Billion US$), 2010-2015
Figure 5-36: Global: Avastin Market: Sales Value (in Billion US$), 2010-2015
Figure 5-37: Global: Lantus Market: Sales Value (in Billion US$), 2010-2015
Figure 5-38: Global: Biopharmaceutical Industry: Value Chain Analysis
Figure 5-39: Biopharmaceutical Industry: Porter’s Five Forces Analysis
Figure 6-1: United States: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 6-2: United States: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 6-3: United States: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 6-4: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 6-5: United States: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 6-6: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 6-7: United States: Purified Proteins Market (in Million US$), 2009-2016
Figure 6-8: United States: Purified Proteins Market: Sales Share by Class (in %), 2016
Figure 6-9: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 6-10: United States: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 6-11: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 6-12: Canada: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 6-13: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 6-14: Canada: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 6-15: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 6-16: Canada: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 6-17: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 6-18: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 6-19: Canada: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 6-20: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 7-1: Mexico: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 7-2: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 7-3: Mexico: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 7-4: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 7-5: Mexico: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 7-6: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 7-7: Mexico: Purified Proteins Market (in ‘000 US$), 2009-2016
Figure 7-8: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 7-9: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 7-10: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 7-11: Brazil: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 7-12: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 7-13: Brazil: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 7-14: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 7-15: Brazil: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 7-16: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 7-17: Brazil: Purified Proteins Market (in Million US$), 2009-2016
Figure 7-18: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 7-19: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 7-20: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 7-21: Argentina: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 7-22: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 7-23: Argentina: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 7-24: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 7-25: Argentina: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 7-26: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 7-27: Argentina: Purified Proteins Market (in Million US$), 2009-2016
Figure 7-28: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 7-29: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 7-30: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8-1: Germany: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 8-2: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 8-3: Germany: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 8-4: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 8-5: Germany: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 8-6: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 8-7: Germany: Purified Proteins Market (in Million US$), 2009-2016
Figure 8-8: Germany: Purified Proteins Market: Sales Share by Class (in %), 2016
Figure 8-9: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 8-10: Germany: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 8-11: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8-12: France: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 8-13: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 8-14: France: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 8-15: France: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 8-16: France: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 8-17: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 8-18: France: Purified Proteins Market (in Million US$), 2009-2016
Figure 8-19: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 8-20: France: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 8-21: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8-22: Italy: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 8-23: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 8-24: Italy: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 8-25: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 8-26: Italy: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 8-27: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 8-28: Italy: Purified Proteins Market (in Million US$), 2009-2016
Figure 8-29: Italy: Biopharmaceutical Market: Sales Share of Top players (in %), 2016
Figure 8-30: Italy: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 8-31: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8-32: Spain: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 8-33: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 8-34: Spain: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 8-35: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 8-36: Spain: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 8-37: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 8-38: Spain: Purified Proteins Market (in Million US$), 2009-2016

Figure 8-39: Spain: Purified Proteins Market: Sales Share by Class (in %), 2016
Figure 8-40: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 8-41: Spain: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 8-42: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8-43: UK: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 8-44: UK: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 8-45: UK: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 8-46: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 8-47: UK: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 8-48: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 8-49: UK: Purified Proteins Market (in Million US$), 2009-2016
Figure 8-50: UK: Purified Proteins Market: Sales Share by Class (in %), 2016
Figure 8-51: UK: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 8-52: UK: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 8-53: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8-54: Russia: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 8-55: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 8-56: Russia: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 8-57: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 8-58: Russia: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 8-59: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 8-60: Russia: Purified Proteins Market (in Million US$), 2009-2016
Figure 8-61: Russia: Purified Proteins Market: Sales Share by Class (in %), 2016
Figure 8-62: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 8-63: Russia: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 8-64: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 8-65: Turkey: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 8-66: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 8-67: Turkey: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 8-68: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 8-69: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 8-70: Turkey: Purified Proteins Market (in Million US$), 2009-2016
Figure 8-71: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 8-72: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 8-73: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9-1: Japan: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 9-2: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 9-3: Japan: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 9-4: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 9-5: Japan: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 9-6: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 9-7: Japan: Purified Proteins Market (in Million US$), 2009-2016
Figure 9-8: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 9-9: Japan: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 9-10: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9-11: China: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 9-12: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 9-13: China: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 9-14: China: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 9-15: China: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 9-16: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 9-17: China: Purified Proteins Market (in Million US$), 2009-2016
Figure 9-18: China: Purified Proteins Market: Sales Share by Class (in %), 2016
Figure 9-19: China: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 9-20: China: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 9-21: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9-22: Australia: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 9-23: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 9-24: Australia: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 9-25: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 9-26: Australia: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 9-27: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 9-28: Australia: Purified Proteins Market (in Million US$), 2009-2016
Figure 9-29: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 9-30: Australia: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 9-31: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9-32: South Korea: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 9-33: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 9-34: South Korea: Recombinant Proteins Market (in Million US$), 2008-2016
Figure 9-35: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 9-36: South Korea: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 9-37: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2016
Figure 9-38: South Korea: Purified Proteins Market (in Million US$), 2009-2016
Figure 9-39: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2016
Figure 9-40: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 9-41: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 9-42: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9-43: India: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 9-44: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 9-45: India: Recombinant Proteins Market (in Million US$), 2009-2016
Figure 9-46: India: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 9-47: India: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 9-48: India: Purified Proteins Market (in Million US$), 2009-2016
Figure 9-49: India: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 9-50: India: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 9-51: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 9-52: Indonesia: Biopharmaceutical Market (in Million US$), 2009-2016
Figure 9-53: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2009-2016
Figure 9-54: Indonesia: Recombinant Proteins Market (in Million US$), 2008-2016
Figure 9-55: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2016
Figure 9-56: Indonesia: Monoclonal Antibodies Market (in Million US$), 2009-2016
Figure 9-57: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2016
Figure 9-58: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2016
Figure 9-59: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2017-2021
Figure 9-60: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
Figure 10-1: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2000& 2015
Figure 10-2: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
Figure 10-3: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
Figure 10-4: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
Figure 10-5: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 10-6: Comparison of the Annual Cost of Therapy for Plaque Psoriasis Using Biopharmaceuticals and Small Molecule Drugs (in US$)
Figure 10-7: Emerging Biopharmaceutical Market Forecast (in Million US$), 2016 & 2021
Figure 10-8: Developed Biopharmaceutical Market Forecast (in Million US$), 2016 & 2021
Figure 10-9: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2001-2016
Figure 10-10: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in %), 2001-2016
Figure 10-11: Global: Breakup of Small Molecule Drugs and Biopharmaceuticals in the Total Pharmaceutical Market & Phase III development (%)
Figure 10-12: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
Figure 10-13: Research and Development Times Taken by Biopharmaceuticals to Reach the Market (in Months), 1982-89,1990-94,1995-99, 2000-04, 2005-09
Figure 10-14: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)
Figure 10-15: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars:  Patient Share (in %), 2007-2011
Figure 10-16: Germany, France, Italy, Spain & UK: Epoetin AlfaBiosimilars:  Patient Share (in %), 2007-2011
Figure 10-17: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars:  Patient Share (in %), 2008-2011
Figure 10-18: Current Medicare Payer Coverage for Monoclonal Antibodies
Figure 10-19: Performance of Biotech Stocks During the Financial Crisis (in %), Jan 2008 to Dec 2008

List of Tables

Table 2-1: Global: Biopharmaceutical Market: Definition & Segmentation 
Table 3-1: Global: Biopharmaceutical Market: SWOT Analysis 
Table 3-2: Global: Biopharmaceutical Market Forecast: Sales by Region (In Million US$), 2017 & 2021
Table 4-1: Differences Between Small Molecule Drugs & Biopharmaceuticals 
Table 4-2: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs 
Table 5-1: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2009-2016
Table 5-2: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2017-2021
Table 5-3: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2016
Table 5-4: Global: Contribution of Various Classes to Total Biopharmaceutical Growth (in Million US$), 2017-2021
Table 5-5: Roche: Financial Data (in US$ Million), 2011-2015
Table 5-6: Amgen: Financial Data (in US$ Million), 2011-2015
Table 5-7: Novo Nordisk: Financial Data (in US$ Million), 2011-2015
Table 5-8: AbbVie: Financial Data (in US$ Million), 2011-2015
Table 5-9: Sanofi S.A.: Financial Data (in US$ Million), 2011-2015
Table 5-10: Global: Biopharmaceutical Market: Sales of Top Biopharmaceuticals (in Million US$), 2015
Table 10-1: Global: Top Ten Selling Drugs (Based on Origin), 2000
Table 10-2: Global: Top Ten Selling Drugs (Based on Origin), 2015
Table 10-3: Mode of Administration of Popular Biotech Drugs
Table 10-4: FDA: Total Number of Biopharmaceutical Approvals in 2015


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Special Prices


    IMARC provides special pricing for:

  • Academic Institutes
  • Government Agencies
  • Nonprofit Organizations
  • For more information, feel free to contact us.






Related Report

Global Biopharmaceutical Manufacturing Market Report 2017-2021

IMARC Group’s latest report titled “Global Biopharmaceutical Manufacturing Market Report 2017-2021” provides a detailed analysis on the global biopharmaceutical manufacturing industry. Biopharmaceuticals represent one of the most elegant and sophisticated achievements of modern science. Compar...


Global Portable Medical and Healthcare Devices Market Report (Cardiac Monitoring Devices, Blood Glucose Monitoring, Pulse Oximetry Devices, Wearable BP Monitors, Smart Wrist-Wearables, Smart Garments etc.) (2017-2021)

The health of a citizen directly affects the productivity and growth of a country’s economy. Therefore, the expenditure on maintaining a good health becomes indispensable. A study has revealed a considerable increment in the heart related problems worldwide which often requires treatment paired wi...


Canada Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022

The report entitled “Canada Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022” represents an in-depth analysis on the historical, current and future trends in the generic drug market in Canada. This research report serves as an exceptional tool to unde...


Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022

The report entitled “Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022” represents an in-depth analysis on the historical, current and future trends in the generic drug market in Japan. This research report serves as an exceptional tool to unders...


Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022

The report entitled “Brazil Generic Drug Market: Industry Trends, Share, Size, Growth, Forecast and Opportunity 2017-2022” represents an in-depth analysis on the historical, current and future trends in the generic drug market in Brazil. This research report serves as an exceptional tool to unde...